{"filings":[{"id":927877,"accession_number":"0001104659-26-071595","cik":1235912,"company_name":"CVRx, Inc.","ticker":"CVRX","form_type":"8-K","filed_at":"2026-06-09T12:00:35+00:00","items":["5.02","9.01"],"status":"ready","headline":"CVRx CFO Jared Oasheim steps down, will remain as advisor through February 2027","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jared Oasheim notified CVRx of his resignation as CFO on June 7, 2026, to pursue other opportunities.","He will remain CFO until a successor starts and then serve as a consultant at $245 per hour until February 2027.","CVRx agreed to pay Oasheim $262,000 for transition and consulting, plus extend option exercise and reimburse up to $10,000 in legal fees.","The company has initiated a search for a new CFO; Oasheim will still present at Goldman Sachs Healthcare Conference on June 10, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":152252637.93273354,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":835316,"accession_number":"0001104659-26-070139","cik":1235912,"company_name":"CVRx, Inc.","ticker":"CVRX","form_type":"8-K","filed_at":"2026-06-03T20:49:03+00:00","items":["5.07"],"status":"ready","headline":"CVRx shareholders elect three Class II directors, ratify auditor at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Michael Dale: 13,261,467 for, 24,036 withheld; Kevin Hykes: 12,040,949 for, 1,244,554 withheld; Joseph Slattery: 11,938,599 for, 1,346,904 withheld.","Ratification of Grant Thornton LLP as independent auditor for FY 2026: 21,150,201 for, 2,275,126 against, 13,855 abstentions.","Broker non-votes of 10,153,679 for each director nominee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":152252637.93273354,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":13085,"accession_number":"0001104659-26-058655","cik":1235912,"company_name":"CVRx, Inc.","ticker":"CVRX","form_type":"8-K","filed_at":"2026-05-11T20:10:52+00:00","items":["2.02","9.01"],"status":"ready","headline":"CVRx Q1 revenue $14.8M (+20% YoY); raises FY gross margin guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["U.S. revenue $13.7M (+22% YoY); active implanting centers grew to 257 from 227 a year ago.","Net loss $13.1M ($0.50 EPS) vs $13.8M ($0.53 EPS) in Q1 2025.","First site activated and first patient enrolled in BENEFIT-HF trial; could expand indicated population ~3x.","FY2026 guidance: revenue $63-67M; gross margin raised to 85-87% from prior 84-86%.","Cash $72.3M; Q2 2026 revenue expected $15.1-16.1M."],"consensus_eps_estimate":-0.5144,"consensus_eps_actual":-0.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":14769000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":152252637.93273354,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91782,"accession_number":"0001104659-26-042354","cik":1235912,"company_name":"CVRx, Inc.","ticker":"CVRX","form_type":"8-K","filed_at":"2026-04-13T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"CVRx reports preliminary Q1 2026 revenue $14.7-14.8M, +20% YoY; gross margin 87%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue expected $14.7-14.8M vs $12.3M in Q1 2025, ~20% growth.","Gross margin ~87% (84% in Q1 2025); operating expenses ~$25M vs $23.7M.","Cash and equivalents ~$72.3M at Mar 31, 2026; active implanting centers 257 (+5 vs Dec 2025).","Medicare Advantage 30-day approval rate rose to 50% in Jan-Feb 2026 vs 44% in 2025 and 31% in 2024.","First site activated in BENEFIT-HF trial on Mar 31; enrollment expected Q2 2026."],"consensus_eps_estimate":-0.5144,"consensus_eps_actual":-0.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":14769000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":152252637.93273354,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102117,"accession_number":"0001104659-26-022952","cik":1235912,"company_name":"CVRx, Inc.","ticker":"CVRX","form_type":"8-K","filed_at":"2026-03-03T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"CVRx grants incremental PSUs to executives tied to cumulative revenue for 2026-2027","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Compensation Committee approved incremental PSU awards for all executive officers with grant date value = 75% of 2026 annual LTI.","PSUs vest based on achievement of undisclosed cumulative revenue goal for 2026-2027; payout ranges from 50% (threshold) to 200% (maximum) of target.","Any earned PSUs vest 50% after certification (by Mar 1, 2028) and 50% on Dec 31, 2028, subject to continued employment.","Target revenue goal not disclosed due to competitive sensitivity; committee believes it represents meaningful revenue growth.","Form of Performance Stock Unit Agreement filed as Exhibit 10.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":152252637.93273354,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102116,"accession_number":"0001104659-26-014303","cik":1235912,"company_name":"CVRx, Inc.","ticker":"CVRX","form_type":"8-K","filed_at":"2026-02-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CVRx Q4 2025 revenue $16.0M (+4% YoY); net loss $11.9M; FY2026 rev guidance $63-67M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $16.0M (US $14.9M, Europe $1.1M); gross margin 86% vs 83% YoY.","Net loss $11.9M ($0.46/sh) vs $10.7M ($0.43/sh) in Q4 2024; full year net loss $53.3M ($2.04/sh).","Active US implanting centers 252 (up 29 YoY); 53 US sales territories; BENEFIT-HF trial enrollment expected Q2 2026.","Jan 2026 amended debt facility: added $10M borrowing to $60M total, interest-only period extended, maturity May 2031.","FY2026 guidance: revenue $63-67M, gross margin 84-86%, op. expenses $103-107M; Q1 2026 revenue expected $13.7-14.7M."],"consensus_eps_estimate":-0.4476,"consensus_eps_actual":-2.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":56651000.0,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":152252637.93273354,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102115,"accession_number":"0001104659-26-002743","cik":1235912,"company_name":"CVRx, Inc.","ticker":"CVRX","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"CVRx enters into $50M at-the-market equity offering agreement with Jefferies","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Up to $50M in common stock may be sold from time to time via ATM offering through Jefferies LLC.","Jefferies receives commission up to 3% of gross proceeds; net proceeds for working capital and general corporate purposes.","Sales under effective S-3 registration statement (Dec 15, 2025); no obligation to sell any shares.","Agreement contains customary representations, indemnification, and termination provisions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":152252637.93273354,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102114,"accession_number":"0001104659-26-002728","cik":1235912,"company_name":"CVRx, Inc.","ticker":"CVRX","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["1.01","2.02","2.03","8.01","9.01"],"status":"ready","headline":"CVRx amends debt facility to $100M, draws $10M; Q4 rev ~$16M (+4-5% YoY)","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Debt facility increased by $50M to $100M; $10M drawn at closing, total outstanding $60M; maturity extended to May 2031.","Q4 2025 preliminary revenue $15.9-16.1M (+4-5% YoY); full-year 2025 revenue $56.5-56.7M (+10-11% YoY).","FY2026 guidance: revenue $63-67M (+11-18% YoY); gross margin 84-86%; operating expenses $103-107M.","BENEFIT-HF trial: FDA IDE granted Nov 2025; applied for CMS coverage; net trial costs $20-30M over 5-7 years.","Cash and equivalents $75.7M as of Dec 31, 2025; 252 active implanting centers; 53 sales territories."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":152252637.93273354,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118441,"accession_number":"0001104659-25-107013","cik":1235912,"company_name":"CVRx, Inc.","ticker":"CVRX","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CVRx Q3 2025 revenue $14.7M (+10% YoY), net loss $12.9M; CMS approves favorable CPT codes for 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $14.7M, up 10% YoY; U.S. revenue $13.5M (+10%); Europe revenue $1.2M (+12%).","Net loss $12.9M ($0.49/share) vs $13.1M ($0.57/share) in Q3 2024; per-share loss improved.","U.S. active implanting centers reached 250, up 20% year-over-year.","CMS finalized Category I CPT codes for Barostim, improving patient access and removing adoption barriers.","FY2025 guidance: revenue $55.6M-$56.6M (narrowed from $55M-$57M), gross margin 85%-86% (raised from 83%-84%)."],"consensus_eps_estimate":-0.5115,"consensus_eps_actual":-1.59,"consensus_revenue_estimate":null,"consensus_revenue_actual":40627000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":152252637.93273354,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134873,"accession_number":"0001104659-25-073638","cik":1235912,"company_name":"CVRx, Inc.","ticker":"CVRX","form_type":"8-K","filed_at":"2025-08-04T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"CVRx Q2 revenue up 15% to $13.6M; narrows FY25 guidance; names COO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2025 revenue $13.6M (+15% YoY); U.S. HF revenue $12.1M (+15%); net loss $14.7M ($0.57/share).","Cash and equivalents $95.0M; net cash used in ops/investing $8.0M vs $10.2M prior year.","Full-year 2025 revenue guidance narrowed to $55-57M (from $55-58M); Q3 2025 revenue expected $13.7-14.7M.","CMS proposed keeping Barostim in APC 1580 for 2026 at ~$45,000 payment; Category I CPT codes set for Jan 2026.","Appointed Brent Binkowski as COO effective Aug 11, 2025; base salary $405k, equity awards of 74,900 options and 16,600 RSUs."],"consensus_eps_estimate":-0.5304,"consensus_eps_actual":-1.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":25937000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":152252637.93273354,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151814,"accession_number":"0001104659-25-056843","cik":1235912,"company_name":"CVRx, Inc.","ticker":"CVRX","form_type":"8-K","filed_at":"2025-06-05T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"CVRx stockholders re-elect Ballinger and Hill as Class I directors; ratify Grant Thornton as auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Kevin Ballinger received 15,182,085 votes for, 848,042 withheld, and 6,965,421 broker non-votes.","Mitch Hill received 14,338,976 votes for, 1,691,151 withheld, and 6,965,421 broker non-votes.","Ratification of Grant Thornton LLP as auditor for FY2025 passed with 22,940,803 for, 52,397 against, 2,348 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":152252637.93273354,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151813,"accession_number":"0001104659-25-046109","cik":1235912,"company_name":"CVRx, Inc.","ticker":"CVRX","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CVRx Q1 revenue $12.3M (+15% YoY); net loss narrows; guides FY2025 rev $55-58M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $12.3M (+15% YoY); U.S. HF revenue $11.1M (+14%) on 353 implants.","Net loss $13.8M ($0.53/share) vs $22.2M ($1.04) in Q1 2024; cash $102.7M.","FY2025 revenue guidance $55-58M; Q2 revenue expected $13-14M.","Active U.S. implanting centers 227 (+19% YoY); gross margin 84%.","Real-world evidence: 85% reduction in HF hospital visits (Premier Healthcare Database)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":12348000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":152252637.93273354,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151812,"accession_number":"0001104659-25-032626","cik":1235912,"company_name":"CVRx, Inc.","ticker":"CVRX","form_type":"8-K","filed_at":"2025-04-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CVRx preliminary Q1 revenue $12.3M (+15% YoY) but below expectations; cites seasonality, new rep ramp","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q1 2025 revenue ~$12.3M, up 15% YoY from $10.8M.","U.S. revenue ~$11.2M; European revenue ~$1.1M.","Active U.S. implant centers 227 (up from 223 at year-end); sales territories reduced to 45.","Cash and equivalents $102.7M; issued 543,462 shares for $9.5M under ATM in Q1.","CEO noted revenue fell short due to new sales reps developing and Q1 seasonality; full results due May 8."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":12348000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":152252637.93273354,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170689,"accession_number":"0001104659-25-009115","cik":1235912,"company_name":"CVRx, Inc.","ticker":"CVRX","form_type":"8-K","filed_at":"2025-02-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CVRx Q4 2024 revenue $15.3M (+36% YoY); FY2025 revenue guidance $63-65M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 total revenue $15.3M, +36% YoY; U.S. HF revenue $14.3M, +41% YoY (457 units vs 330).","FY2024 total revenue $51.3M, +31% YoY; net loss $60.0M ($2.65 per share) vs $41.2M in FY2023.","Active implanting centers grew to 223 as of Dec 31, 2024, up 25% from 178 a year earlier.","FY2025 guidance: total revenue $63-65M, gross margin 83-84%, operating expenses $100-104M.","Cash and cash equivalents $105.9M as of Dec 31, 2024; net cash used in ops/investing $40.5M in FY2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.65,"consensus_revenue_estimate":null,"consensus_revenue_actual":51292000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":152252637.93273354,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170688,"accession_number":"0001104659-25-002873","cik":1235912,"company_name":"CVRx, Inc.","ticker":"CVRX","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"CVRx reports Q4 2024 preliminary revenue $15.2-15.3M (+35% YoY), issues FY2025 guidance $63-65M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 revenue $15.2–15.3M, up 35% from $11.3M; U.S. $14.2–14.3M, Europe $1.0M.","FY2024 revenue $51.1–51.2M (+30% YoY); U.S. $47.0–47.1M, Europe $4.1M.","FY2025 guidance: revenue $63–65M (23–27% growth), gross margin 83–84%, opex $100–104M.","Q1 2025 revenue guidance $14.5–15.0M.","Active U.S. implanting centers 223 (up from 208); cash $105.9M; ATM raised $12.8M via 869K shares."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.65,"consensus_revenue_estimate":null,"consensus_revenue_actual":51292000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":152252637.93273354,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187667,"accession_number":"0001104659-24-113676","cik":1235912,"company_name":"CVRx, Inc.","ticker":"CVRX","form_type":"8-K","filed_at":"2024-11-04T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"CMS assigns Barostim to APC 1580; payment ~$45,000 continues in 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Centers for Medicare and Medicaid Services assigned Barostim procedure to New Technology APC 1580.","APC payment of approximately $45,000 will continue in 2025 per Medicare OPPS final rule.","Announcement on November 4, 2024, confirms favorable reimbursement for CVRx's Barostim therapy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":152252637.93273354,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187666,"accession_number":"0001104659-24-112235","cik":1235912,"company_name":"CVRx, Inc.","ticker":"CVRX","form_type":"8-K","filed_at":"2024-10-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CVRx Q3 revenue rose 27% to $13.4M; net loss widened to $13.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["US HF revenue $12.2M (+30% YoY) driven by territory expansion and new accounts.","Net loss of $13.1M ($0.57/share) vs $9.0M ($0.43/share) a year ago; SG&A expenses up 38%.","Active implanting centers reached 208, up 31% YoY; cash $100.2M after drawing $20M loan tranche.","CMS reassigned Barostim to MS-DRG 276, raising inpatient payment to ~$43,000 from $17-23K.","FY2024 revenue guidance narrowed to $50.5-51.5M (from $50-53M); operating expense guidance raised to ~$100M."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":35950000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":152252637.93273354,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187665,"accession_number":"0001104659-24-104933","cik":1235912,"company_name":"CVRx, Inc.","ticker":"CVRX","form_type":"8-K","filed_at":"2024-10-01T23:59:59+00:00","items":["2.03"],"status":"ready","headline":"CVRx draws $20M final tranche from Innovatus, total debt reaches $50M","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Borrowed $20.0 million under the third and final tranche of its term loan facility with Innovatus Life Sciences Fund I, LP on Sept 30, 2024.","Outstanding term loans under the Innovatus facility now total $50.0 million.","The loan is a direct financial obligation reported under Item 2.03.","Use of proceeds was not specified in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":152252637.93273354,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204139,"accession_number":"0001104659-24-096051","cik":1235912,"company_name":"CVRx, Inc.","ticker":"CVRX","form_type":"8-K","filed_at":"2024-09-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CVRx appoints Ballinger and Hill to board; Behbahani resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kevin Ballinger and Mitch Hill appointed as Class I directors, effective Sept 3, 2024.","Ali Behbahani resigned from the board effective Sept 2, 2024.","Board size increased to seven; Ballinger on Nominating/Governance, Hill on Audit/Comp.","Both new directors determined independent under Nasdaq listing standards."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":152252637.93273354,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204138,"accession_number":"0001104659-24-083543","cik":1235912,"company_name":"CVRx, Inc.","ticker":"CVRX","form_type":"8-K","filed_at":"2024-07-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CVRx Q2 2024 revenue up 24% to $11.8M; net loss widens to $14.0M; updates FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2024 revenue $11.8M (+24% YoY); U.S. HF revenue $10.5M (+27% YoY); net loss $14.0M ($0.65/share) vs $11.6M ($0.56) in Q2 2023.","Active implanting centers in U.S. reach 189, up 35% YoY; sales territories expanded to 42 from 39 in Q1.","Cash and equivalents $70.4M; net cash used in operating/investing $10.2M in Q2, down from $11.8M in Q1.","Hired Robert John as CRO, Dr. Philip Adamson as CMO, and other execs to strengthen commercial efforts.","FY 2024 guidance: revenue $50-53M; gross margin 83-85%; operating expenses $95-98M (narrowed from $92-98M); Q3 revenue $12.7-13.7M."],"consensus_eps_estimate":-0.5304,"consensus_eps_actual":-1.69,"consensus_revenue_estimate":null,"consensus_revenue_actual":22577000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":152252637.93273354,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220868,"accession_number":"0001104659-24-069657","cik":1235912,"company_name":"CVRx, Inc.","ticker":"CVRX","form_type":"8-K","filed_at":"2024-06-07T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"CVRx shareholders approve officer exculpation amendment and elect three Class III directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment to allow officer exculpation under Delaware law approved with 15.3M for, 991K against.","Class III directors Mudit Jain, Kirk Nielsen, Martha Shadan elected; each received >13.8M votes for.","Ratification of Grant Thornton LLP as independent auditor for FY 2024 passed with 19.7M for, 118K against.","Total shares voted: 19.9M for auditor; broker non-votes 3.6M on director and amendment proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":152252637.93273354,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220867,"accession_number":"0001104659-24-068492","cik":1235912,"company_name":"CVRx, Inc.","ticker":"CVRX","form_type":"8-K","filed_at":"2024-06-05T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"CVRx reaffirms FY2024 revenue guidance of $50-53M and Q2 revenue of $11.3-12.3M","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Full-year 2024 revenue reaffirmed at $50M-$53M; gross margin 83%-85%; OpEx $92M-$98M.","Q2 2024 revenue expected between $11.3M and $12.3M.","Management presenting at William Blair 44th Annual Growth Stock Conference on June 5, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":152252637.93273354,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220866,"accession_number":"0001104659-24-054933","cik":1235912,"company_name":"CVRx, Inc.","ticker":"CVRX","form_type":"8-K","filed_at":"2024-04-30T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"CVRx Q1 revenue $10.8M (+35% YoY); net loss $22.2M; FY guidance $50-53M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $10.8M (+35% YoY); US HF revenue $9.7M (+43%); active implanting centers 190 (+56% YoY).","Net loss $22.2M ($1.04/shr) vs $11.4M ($0.55) prior year; SG&A $28.3M (+84%) from stock-based comp modification for former CEO.","Full-year 2024 revenue guidance $50-53M; Q2 2024 revenue expected $11.3-12.3M.","Kevin Hykes appointed CEO Feb 12; BeAT-HF data published in European Journal of Heart Failure.","Compensation Committee approved $50k bonus to Paul Verrastro for management transition support."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":10770000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":152252637.93273354,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240466,"accession_number":"0001104659-24-008555","cik":1235912,"company_name":"CVRx, Inc.","ticker":"CVRX","form_type":"8-K","filed_at":"2024-01-31T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"CVRx appoints Kevin Hykes as President and CEO effective Feb 12, 2024; Yared retires","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Hykes, a board member since Dec 2022, succeeds Nadim Yared who retires Feb 11, 2024 and will consult through Dec 2024 at $550/hr.","Hykes receives $640K base salary, 75% target cash incentive, $150K sign-on bonus, and option for 360K shares vesting over 4 years.","Option grant is an inducement award under Nasdaq Rule 5635(c)(4) with exercise price equal to closing price on Feb 12, 2024.","Hykes brings 30 years med device experience; previously CEO of Augmedics, Bardy Diagnostics, Relievant Medsystems, and Cameron Health."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":152252637.93273354,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240465,"accession_number":"0001104659-24-006675","cik":1235912,"company_name":"CVRx, Inc.","ticker":"CVRX","form_type":"8-K","filed_at":"2024-01-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CVRx Q4 revenue $11.3M (+58% YoY); CEO Nadim Yared to retire; FY23 rev $39.3M (+75%)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $11.3M (+58% YoY); US HF revenue $10.2M (+70% YoY).","FY23 revenue $39.3M (+75% YoY); net loss $41.2M ($1.99/share); cash $90.6M.","Active implanting centers 178 at year-end, up from 106 in prior year.","CEO Nadim Yared announces retirement; board to conduct succession search; Yared stays until successor appointed.","FDA approved expanded Barostim labeling; CMS increased outpatient payment to ~$45,000; market opportunity updated to $2.2B annually."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.99,"consensus_revenue_estimate":null,"consensus_revenue_actual":39295000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":152252637.93273354,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240464,"accession_number":"0001104659-24-002089","cik":1235912,"company_name":"CVRx, Inc.","ticker":"CVRX","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["2.02","5.02","8.01","9.01"],"status":"ready","headline":"CVRx reports prelim Q4 revenue ~$11.2M (+57% YoY), FY2023 ~$39.2M (+74%); CEO Yared plans retirement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary Q4 2023 revenue $11.2M-$11.3M, up 56-58% YoY from $7.2M.","Preliminary FY2023 revenue $39.2M-$39.3M, up 74-75% YoY from $22.5M.","FY2024 guidance: revenue $53M-$57M, gross margin 83-84%, OpEx $86M-$90M.","Active implanting centers grew to 178 (up from 159); cash $91M as of Dec 31, 2023.","CEO Nadim Yared plans to retire after successor identified; board search underway."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":152252637.93273354,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257978,"accession_number":"0001104659-23-129004","cik":1235912,"company_name":"CVRx, Inc.","ticker":"CVRX","form_type":"8-K","filed_at":"2023-12-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"CVRx receives FDA approval for expanded Barostim labeling; annual market opportunity increases to $2.2B","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved revised Instructions For Use for Barostim incorporating long-term BeAT-HF trial data (NYHA Class III/II, EF ≤35%, NT-proBNP <1600 pg/ml).","Clinical Summary includes 6/12/24-month data, win ratio, all-cause mortality; primary safety endpoint met, but CV death+HF hospitalization endpoint not met.","U.S. annual market opportunity revised to $2.2B (76,000 new patients) from $1.4B (55,000), increases of ~60% and 38%.","CEO Nadim Yared highlighted validation of long-term results and ability to share data with physicians and patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":152252637.93273354,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257977,"accession_number":"0001104659-23-126426","cik":1235912,"company_name":"CVRx, Inc.","ticker":"CVRX","form_type":"8-K","filed_at":"2023-12-15T23:59:59+00:00","items":["2.03"],"status":"ready","headline":"CVRx borrows $15M second tranche from Innovatus; total debt outstanding $30M","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Borrowed $15.0 million under second tranche of Innovatus term loan facility on Dec. 15, 2023.","Total outstanding term loans under the facility are now $30.0 million.","Additional tranche of up to $20.0 million remains available subject to conditions.","The draw was made on the deadline for the second tranche under the loan agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":152252637.93273354,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257976,"accession_number":"0001104659-23-111750","cik":1235912,"company_name":"CVRx, Inc.","ticker":"CVRX","form_type":"8-K","filed_at":"2023-10-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CVRx Q3 revenue up 70% to $10.5M, raises FY2023 revenue guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $10.5M (+70% YoY); U.S. HF revenue $9.4M (+92% YoY).","Net loss $9.0M ($0.43/sh) vs $9.8M ($0.48/sh) in Q3 2022; cash burn improved to $8.2M from $13.0M in Q2.","Active implanting centers 159 (+75% YoY); sales territories grew to 35.","FY2023 revenue guidance raised to $38.5M-$39.0M (from $37.0M-$38.5M); Q4 revenue expected $10.5M-$11.0M.","CMS advisory panel unanimously recommended higher Barostim payment code; final rule expected late Nov."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.55,"consensus_revenue_estimate":null,"consensus_revenue_actual":27990000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":152252637.93273354,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275298,"accession_number":"0001104659-23-083850","cik":1235912,"company_name":"CVRx, Inc.","ticker":"CVRX","form_type":"8-K","filed_at":"2023-07-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CVRx Q2 revenue $9.5M (+89% YoY); raises FY 2023 revenue guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 total revenue $9.5M, +89% YoY; US HF revenue $8.3M, +119% YoY.","Net loss $11.7M ($0.56 per share) vs $11.1M ($0.54 per share) in Q2 2022.","Active US implanting centers grew to 140, up 97% from June 2022.","FY 2023 revenue guidance raised to $37.0-38.5M (from $35.5-38.0M).","PMA supplement filed with FDA for Barostim indication expansion in June 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":17479000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":152252637.93273354,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292758,"accession_number":"0001104659-23-069165","cik":1235912,"company_name":"CVRx, Inc.","ticker":"CVRX","form_type":"8-K","filed_at":"2023-06-08T23:59:59+00:00","items":["5.07","7.01","9.01"],"status":"ready","headline":"CVRx annual meeting results and William Blair conference presentation","summary_kind":"llm","event_type":"other","confidence":"medium","bullets":["Class II directors Kevin Hykes and Joseph Slattery elected with 12.4M and 11.9M votes respectively; 5.8M broker non-votes.","Ratification of Grant Thornton LLP as independent auditor for FY2023 approved (18.8M for, 641 against, 9,526 abstain).","Company to present at the 43rd Annual William Blair Growth Stock Conference on June 8, 2023; materials furnished as Exhibit 99.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":152252637.93273354,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292757,"accession_number":"0001104659-23-051393","cik":1235912,"company_name":"CVRx, Inc.","ticker":"CVRX","form_type":"8-K","filed_at":"2023-04-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CVRx Q1 revenue $8.0M (+96% YoY); US HF sales surge 132%; raises full-year guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $11.4M ($0.55 per share) vs $10.0M ($0.49) in prior year quarter.","U.S. heart failure revenue $6.8M (+132% YoY); active implanting centers grew to 122 (118% YoY).","FY 2023 revenue guidance raised to $35.5M-$38.0M (prior $35M-$38M); gross margin guidance improved to 80%-83%.","Q2 2023 revenue expected between $8.2M and $8.8M; operating expenses $76M-$80M for full year.","Cash and equivalents $103.3M at quarter end; net cash used in ops and investing $10.5M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.55,"consensus_revenue_estimate":null,"consensus_revenue_actual":7979000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":152252637.93273354,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":313412,"accession_number":"0001104659-23-034843","cik":1235912,"company_name":"CVRx, Inc.","ticker":"CVRX","form_type":"8-K","filed_at":"2023-03-21T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"CVRx BeAT-HF trial: safety endpoint met, symptom improvement shown; primary endpoint not significant","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Safety: MANCE event-free rate of 97% (p<0.001).","Symptom improvement: 6-min walk +44m at 12mo, QoL +10 pts at 24mo (p<0.001).","Primary endpoint (CV death, LVAD, transplant, HF hospitalizations) not significant (RR 0.94, p=0.82).","All-cause mortality showed 34% relative reduction favoring BAT (HR 0.66, p=0.054).","CEO plans FDA submission in coming months for expanded labeling."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":152252637.93273354,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":313411,"accession_number":"0001104659-23-032814","cik":1235912,"company_name":"CVRx, Inc.","ticker":"CVRX","form_type":"8-K","filed_at":"2023-03-15T23:59:59+00:00","items":["2.03"],"status":"ready","headline":"CVRx draws remaining $7.5M from Innovatus term loan facility","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Borrowed $7.5M remaining under first tranche of Innovatus term loan facility.","$4M received March 13, $3.5M received March 15, 2023.","Total outstanding term loans now $15M under the facility.","Company cited banking industry uncertainty as reason for draw.","Facility allows up to $35M more in two additional tranches subject to conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":152252637.93273354,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":313410,"accession_number":"0001104659-23-023522","cik":1235912,"company_name":"CVRx, Inc.","ticker":"CVRX","form_type":"8-K","filed_at":"2023-02-21T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"CVRx BeAT-HF trial misses primary endpoint; positive secondary analyses support Barostim label expansion plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Trial of 323 HFrEF patients did not reach statistical significance on primary composite endpoint of CV mortality and HF morbidity.","Prespecified analyses favored Barostim: all-cause survival free from LVAD/transplant, Win Ratio analysis, clinical stability.","Safety and symptomatic improvement at 6 months durable through 24 months.","Company plans to submit totality of evidence to FDA for expanded Barostim labeling.","Data to be presented at THT conference on March 21, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":152252637.93273354,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":313409,"accession_number":"0001104659-23-007029","cik":1235912,"company_name":"CVRx, Inc.","ticker":"CVRX","form_type":"8-K","filed_at":"2023-01-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CVRx Q4 revenue $7.2M (+96% YoY); guides FY2023 revenue $35-38M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2022 total revenue $7.2M, up 96% vs prior year; US HF revenue $6.0M (+121% YoY).","Full year 2022 revenue $22.5M (+72% YoY); net loss $41.4M ($2.02 per share).","Active implanting centers grew 130% to 106 in 2022 from 46 in 2021.","FY2023 guidance: revenue $35-38M, gross margin 78-79%, operating expenses $76-80M.","BeAT-HF trial unblinding and data announcement expected later in Q1 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":22469000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":152252637.93273354,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":313408,"accession_number":"0001104659-23-002098","cik":1235912,"company_name":"CVRx, Inc.","ticker":"CVRX","form_type":"8-K","filed_at":"2023-01-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CVRx reports preliminary Q4 revenue up ~91-94% YoY; FY2023 guidance $35-38M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2022 revenue $7.0-7.1M (+91-94% YoY); U.S. heart failure revenue $5.9M.","FY2022 revenue $22.3-22.4M (+71-72%); 106 active implanting centers (up from 91).","Cash and equivalents $106M as of Dec 31, 2022; 26 U.S. sales territories.","FY2023 guidance: revenue $35-38M, gross margin 78-79%, operating expenses $76-80M.","Q1 2023 revenue expected $7.1-7.5M."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":22469000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":152252637.93273354,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":331923,"accession_number":"0001104659-22-128680","cik":1235912,"company_name":"CVRx, Inc.","ticker":"CVRX","form_type":"8-K","filed_at":"2022-12-20T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CVRx appoints Kevin Hykes as independent director effective Dec 21, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board increased from 7 to 8 members; Hykes appointed as Class II director.","Hykes determined independent under Nasdaq listing standards; no committee assignments yet.","Director compensation per non-employee director program; term expires at 2023 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":152252637.93273354,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":331922,"accession_number":"0001104659-22-113505","cik":1235912,"company_name":"CVRx, Inc.","ticker":"CVRX","form_type":"8-K","filed_at":"2022-11-01T23:59:59+00:00","items":["1.01","2.02","2.03","9.01"],"status":"ready","headline":"CVRx Q3 revenue $6.2M (+82% YoY); raises FY2022 guidance; secures $50M debt facility","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $6.2M (+82% YoY); US HF revenue $4.9M (+99% YoY) on expansion to 91 active implanting centers (from 38).","Net loss $9.8M ($0.48 per share) vs $6.1M ($0.30) YoY; cash and equivalents $110.0M at quarter end.","FY2022 guidance narrowed: revenue $21.8M-$22.3M (prior $20.5M-$23.0M); gross margin 76-77% (prior 75-76%).","BeAT-HF trial reached required 320th event; full unblinding expected first half 2023.","Entered $50M term loan with Innovatus; drew $7.5M at close; interest-only for 5 years, matures Jan 2028."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.51,"consensus_revenue_estimate":null,"consensus_revenue_actual":15293000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":152252637.93273354,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":349386,"accession_number":"0001104659-22-083664","cik":1235912,"company_name":"CVRx, Inc.","ticker":"CVRX","form_type":"8-K","filed_at":"2022-07-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CVRx Q2 revenue $5.0M (+61% YoY); HF revenue up 90% in US; FY guidance raised","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $5.0M (+61% YoY), US HF revenue $3.8M (+90% YoY) driven by territory expansion.","Active US implanting centers reached 71 (+27% QoQ); sales territories grew to 20 from 8 a year ago.","Net loss narrowed to $11.1M ($0.54/shr) from $17.7M; cash $121.3M at quarter end.","FY2022 revenue guidance raised lower end to $20.5M (range $20.5-$23.0M); gross margin guidance 75-76%.","Received FDA approval for new tablet programmer and MR conditional labeling for Barostim."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.49,"consensus_revenue_estimate":null,"consensus_revenue_actual":9107000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":152252637.93273354,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":366305,"accession_number":"0001104659-22-069673","cik":1235912,"company_name":"CVRx, Inc.","ticker":"CVRX","form_type":"8-K","filed_at":"2022-06-09T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"CVRx shareholders re-elect directors, ratify auditor at 2022 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Ali Behbahani re-elected as Class I director: 9,237,017 for, 2,771,501 withheld, 4,469,391 broker non-votes.","Nadim Yared re-elected as Class I director: 10,744,143 for, 1,264,375 withheld, 4,469,391 broker non-votes.","Grant Thornton LLP ratified as independent auditor for FY2022: 16,445,980 for, 31,746 against, 183 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":152252637.93273354,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":366304,"accession_number":"0001104659-22-049634","cik":1235912,"company_name":"CVRx, Inc.","ticker":"CVRX","form_type":"8-K","filed_at":"2022-04-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CVRx Q1 revenue $4.1M (+43% YoY); US HF revenue up 133% to $2.9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $10.0M ($0.49 per share) vs $8.6M loss ($23.92 per share) in Q1 2021; weighted avg shares 20.45M.","U.S. active implanting centers grew to 56 from 19; sales territories expanded to 17 from 6 year-over-year.","Cash $131.2M at Mar 31, 2022; full-year 2022 revenue guidance $20-23M; Q2 expected $4.5-5M.","Received FDA approval for new tablet-form factor programmer in April 2022.","Gross margin improved to 77% from 70%; R&D $2.3M (+29%), SG&A $10.8M (+142%)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.49,"consensus_revenue_estimate":null,"consensus_revenue_actual":4076000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":152252637.93273354,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":385799,"accession_number":"0001104659-22-023796","cik":1235912,"company_name":"CVRx, Inc.","ticker":"CVRX","form_type":"8-K","filed_at":"2022-02-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CVRx posts Q4 revenue $3.7M (+75% YoY); FY2021 revenue $13.0M; guides FY2022 rev $20-23M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2021 revenue $3.7M, up 75% YoY; US HF revenue $2.7M, up 345%.","Full year 2021 revenue $13.0M, up 115% YoY; net loss $43.1M ($4.16 per share).","Guides FY2022 total revenue $20-23M; Q1 2022 revenue $3.6-4.0M; gross margin 74-76%.","Received FDA approval for new IPG in Dec 2021; expects MRI labeling and new programmer approvals in H1 2022.","Fully repaid $20M loan in Nov 2021; cash $142.1M at year-end."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":13036000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":152252637.93273354,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":385798,"accession_number":"0001104659-22-002514","cik":1235912,"company_name":"CVRx, Inc.","ticker":"CVRX","form_type":"8-K","filed_at":"2022-01-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CVRx preliminary Q4 rev $3.6-3.7M (+71-77% YoY); FY2021 rev $13.0-13.1M (+113-116% YoY); FY2022 guidance $20-23M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q4 2021 revenue $3.6-$3.7M, up 71-77% YoY vs $2.1M.","Full year 2021 revenue $13.0-$13.1M, up 113-116% from $6.1M in 2020.","U.S. heart failure revenue $8.4M, Europe $3.9M, U.S. legacy $0.7M for 2021.","Active implanting centers grew to 46 as of Dec 31, 2021 from 38 as of Sep 30, 2021.","FY2022 revenue guidance $20-$23M; Q1 2022 expected $3.6-$4.0M."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":13036000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":152252637.93273354,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":403688,"accession_number":"0001104659-21-134411","cik":1235912,"company_name":"CVRx, Inc.","ticker":"CVRX","form_type":"8-K","filed_at":"2021-11-04T23:59:59+00:00","items":["1.02","2.02","9.01"],"status":"ready","headline":"CVRx reports Q3 revenue $3.4M (+241% YoY); repays $20M loan","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $3.4M (241% YoY increase); U.S. HF revenue $2.5M vs $140K prior year.","Net loss $6.1M ($0.30/share) vs $3.2M ($9.56/share) prior year; cash $170.9M.","Fully repaid $20M Horizon loan on Nov 3, including fees total $21.3M.","FY2021 guidance: revenue $13.3-13.9M; Q4 revenue expected $3.9-4.5M.","Filed three PMA Supplement submissions for Barostim platform; FDA approval expected H1 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.66,"consensus_revenue_estimate":null,"consensus_revenue_actual":9378000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":152252637.93273354,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":422650,"accession_number":"0001104659-21-100076","cik":1235912,"company_name":"CVRx, Inc.","ticker":"CVRX","form_type":"8-K","filed_at":"2021-08-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CVRx Q2 revenue up 150% to $3.1M; IPO nets $133.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $3.1M (+150% YoY); U.S. HF revenue $2.0M (from $65K).","Net loss $17.7M (incl. $11.4M non-cash warrant expense); cash $47.1M.","IPO closed July 2; net proceeds ~$133.3M; 8.05M shares at $18.","Full-year 2021 revenue guidance $13.3-13.9M; Q3 revenue $3.3-3.6M.","Active implanting centers increased to 31; Martha Shadan appointed; first BATwire procedure performed."],"consensus_eps_estimate":null,"consensus_eps_actual":-72.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":5983000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":152252637.93273354,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":422649,"accession_number":"0001104659-21-091174","cik":1235912,"company_name":"CVRx, Inc.","ticker":"CVRX","form_type":"8-K","filed_at":"2021-07-12T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CVRx appoints Martha Shadan as independent director, expanding board to eight","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded from 7 to 8; Martha Shadan appointed effective July 12, 2021.","Shadan serves as Class III director, term expiring at 2024 annual meeting.","Board determined Shadan qualifies as independent under Nasdaq rules; committee assignments pending.","Compensation follows non-employee director program described in July 1, 2021 S-1 prospectus."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":152252637.93273354,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":422648,"accession_number":"0001104659-21-089779","cik":1235912,"company_name":"CVRx, Inc.","ticker":"CVRX","form_type":"8-K","filed_at":"2021-07-07T23:59:59+00:00","items":["5.03","8.01","9.01"],"status":"ready","headline":"CVRx completes IPO of 8.05M shares at $18.00, raising ~$144.9M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["IPO closed July 2, 2021; 8,050,000 shares sold including full over-allotment exercise.","Public offering price $18.00 per share; gross proceeds ~$144.9 million before discount/expenses.","Amended certificate authorizes 200M common shares and 10M undesignated preferred shares.","Classified board with three staggered director classes established.","Exclusive forum provisions for derivative and securities claims adopted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":152252637.93273354,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}